Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
FibroGen (FGEN)
NASDAQ:FGEN
Holding FGEN?
Track your performance easily
FGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.18 - $2.93
Previous Close$0.4
Volume996.68K
Average Volume (3M)1.22M
Market Cap
$39.84M
Enterprise Value$25.59M
Total Cash (Recent Filing)$131.00M
Total Debt (Recent Filing)$74.78M
Price to Earnings (P/E)―
Beta2.53
Next Earnings
Mar 03, 2025EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding100,770,153
10 Day Avg. Volume1,848,524
30 Day Avg. Volume1,218,880
Standard Deviation0.29
R-Squared0.02
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-0.14
Price to Sales (P/S)0.20
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.14
Enterprise Value/Gross Profit0.20
Enterprise Value/Ebitda-0.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
FibroGen News
PremiumCompany Announcements
FibroGen Reports Strong Q3 Growth and Future Plans
PremiumCompany Announcements
FibroGen Cuts Costs by Terminating San Francisco Lease Early
PremiumCompany Announcements
FibroGen Announces Board Member Resignations and Committee Appointments
PremiumCompany Announcements
FibroGen Executives Depart Amid U.S. Operations Overhaul
Ownership Overview
2.97% Insiders
18.72% Mutual Funds
23.16% Other Institutional Investors
49.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FGEN FAQ
What was FibroGen’s price range in the past 12 months?
FibroGen lowest stock price was $0.18 and its highest was $2.93 in the past 12 months.
What is FibroGen’s market cap?
Currently, no data Available
When is FibroGen’s upcoming earnings report date?
FibroGen’s upcoming earnings report date is Mar 03, 2025 which is in 97 days.
How were FibroGen’s earnings last quarter?
FibroGen released its earnings results on Nov 12, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.306 by $0.136.
Is FibroGen overvalued?
According to Wall Street analysts FibroGen’s price is currently Overvalued.
Does FibroGen pay dividends?
FibroGen does not currently pay dividends.
What is FibroGen’s EPS estimate?
FibroGen’s EPS estimate is -$0.22.
How many shares outstanding does FibroGen have?
FibroGen has 100,770,150 shares outstanding.
What happened to FibroGen’s price movement after its last earnings report?
FibroGen reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.306. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of FibroGen?
Among the largest hedge funds holding FibroGen’s share is PRIMECAP Management Co. It holds FibroGen’s shares valued at 4M.
---
FibroGen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
FGEN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.9%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.36%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-42.57%
Trailing 12-Months
Company Description
FibroGen
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
---
FGEN Earnings Call
Q3 2024
0:00 / 0:00
---
FGEN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
Atara Biotherapeutics
―
Akebia Therapeutics
―
Kiniksa Pharmaceuticals
―
Best Analysts Covering FGEN
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+40.78%
reiterated a sell rating 4 months ago
Copying Paul Choi's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +40.78% per trade.
---